RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07062380, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. BCLC stage 0-A, scheduled for curative liver resection.

    Inclusion criterion 2

    Child-Pugh liver function score ≤7.

    Inclusion criterion 5

  3. ECOG Performance Status (PS) 0-1.

    Inclusion criterion 6

  4. Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.

    Inclusion criterion 4

  5. Pregnant or lactating women.

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07062380, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged 18-75 years, regardless of gender.
  • BCLC stage 0-A, scheduled for curative liver resection.
  • Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).
  • Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.
  • Child-Pugh liver function score ≤7.
  • ECOG Performance Status (PS) 0-1.
  • No severe organic diseases of the heart, lungs, brain, or other vital organs.

Exclusion Criteria:

  • Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).
  • Postoperative pathology confirms non-HCC diagnosis.
  • Pregnant or lactating women.
  • History of organ transplantation.
  • Inability to comply with the study protocol or follow-up schedule.

Quoted from ClinicalTrials.gov, NCT07062380, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07062380, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07062380